1399 related articles for article (PubMed ID: 29408986)
1. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
2. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE
J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lu S; Wang J; Cheng Y; Mok T; Chang J; Zhang L; Feng J; Tu HY; Wu L; Zhang Y; Luft A; Zhou JY; Ma Z; Lu Y; Hu C; Shi Y; Ying K; Zhong H; Poddubskaya E; Soo RA; Chia YH; Li A; Li A; Wu YL
Lung Cancer; 2021 Feb; 152():7-14. PubMed ID: 33321441
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
8. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Antonia SJ; Borghaei H; Ramalingam SS; Horn L; De Castro Carpeño J; Pluzanski A; Burgio MA; Garassino M; Chow LQM; Gettinger S; Crinò L; Planchard D; Butts C; Drilon A; Wojcik-Tomaszewska J; Otterson GA; Agrawal S; Li A; Penrod JR; Brahmer J
Lancet Oncol; 2019 Oct; 20(10):1395-1408. PubMed ID: 31422028
[TBL] [Abstract][Full Text] [Related]
9. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Borghaei H; Paz-Ares L; Horn L; Spigel DR; Steins M; Ready NE; Chow LQ; Vokes EE; Felip E; Holgado E; Barlesi F; Kohlhäufl M; Arrieta O; Burgio MA; Fayette J; Lena H; Poddubskaya E; Gerber DE; Gettinger SN; Rudin CM; Rizvi N; Crinò L; Blumenschein GR; Antonia SJ; Dorange C; Harbison CT; Graf Finckenstein F; Brahmer JR
N Engl J Med; 2015 Oct; 373(17):1627-39. PubMed ID: 26412456
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
Borghaei H; O'Byrne KJ; Paz-Ares L; Ciuleanu TE; Yu X; Pluzanski A; Nagrial A; Havel L; Kowalyszyn RD; Valette CA; Brahmer JR; Reck M; Ramalingam SS; Zhang L; Ntambwe I; Rabindran SK; Nathan FE; Balli D; Wu YL
ESMO Open; 2023 Dec; 8(6):102065. PubMed ID: 37988950
[TBL] [Abstract][Full Text] [Related]
13. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Fehrenbacher L; von Pawel J; Park K; Rittmeyer A; Gandara DR; Ponce Aix S; Han JY; Gadgeel SM; Hida T; Cortinovis DL; Cobo M; Kowalski DM; De Marinis F; Gandhi M; Danner B; Matheny C; Kowanetz M; He P; Felizzi F; Patel H; Sandler A; Ballinger M; Barlesi F
J Thorac Oncol; 2018 Aug; 13(8):1156-1170. PubMed ID: 29777823
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Xu Z; Yi F; Yu D; Xu J; Wei Y; Zhang W
Cancer Med; 2019 Feb; 8(2):629-642. PubMed ID: 30628185
[TBL] [Abstract][Full Text] [Related]
15. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
Felip E; Ardizzoni A; Ciuleanu T; Cobo M; Laktionov K; Szilasi M; Califano R; Carcereny E; Griffiths R; Paz-Ares L; Duchnowska R; Garcia MA; Isla D; Jassem J; Appel W; Milanowski J; Van Meerbeeck JP; Wolf J; Li A; Acevedo A; Popat S
Eur J Cancer; 2020 Mar; 127():160-172. PubMed ID: 32028209
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
Clin Drug Investig; 2020 Feb; 40(2):129-137. PubMed ID: 31679121
[TBL] [Abstract][Full Text] [Related]
17. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Zurawski B; Kim SW; Mahave M; Alexandru A; Peters S; Pluzanski A; Caro RB; Linardou H; Burgers JA; Nishio M; Martinez-Marti A; Azuma K; Axelrod R; Paz-Ares LG; Ramalingam SS; Borghaei H; O'Byrne KJ; Li L; Bushong J; Gupta RG; Grootendorst DJ; Eccles LJ; Brahmer JR
J Thorac Oncol; 2023 Aug; 18(8):1055-1069. PubMed ID: 37146754
[TBL] [Abstract][Full Text] [Related]
18. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
[TBL] [Abstract][Full Text] [Related]
20. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
